RARRES1
Retinoic acid receptor responder protein 1
Also known as: LXNL, TIG1, TIG1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P49788
- Gene
- RARRES1
- Ensembl
- ENSG00000118849
- Chromosome
- 3
- Canonical length
- 294 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Endoplasmic reticulum,Golgi apparatus
- Secretome location
- Intracellular and membrane
OverviewNCBI Gene
This gene was identified as a retinoid acid (RA) receptor-responsive gene. It encodes a type 1 membrane protein. The expression of this gene is upregulated by tazarotene as well as by retinoic acid receptors. The expression of this gene is found to be downregulated in prostate cancer, which is caused by the methylation of its promoter and CpG island. Alternatively spliced transcript variant encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
294 residues, UniProt reviewed canonical sequence.
>P49788|RARRES1
1 MQPRRQRLPA PWSGPRGPRP TAPLLALLLL LAPVAAPAGS GDPDDPGQPQ DAGVPRRLLQ
61 QAARAALHFF NFRSGSPSAL RVLAEVQEGR AWINPKEGCK VHVVFSTERY NPESLLQEGE
121 GRLGKCSARV FFKNQKPRPT INVTCTRLIE KKKRQQEDYL LYKQMKQLKN PLEIVSIPDN
181 HGHIDPSLRL IWDLAFLGSS YVMWEMTTQV SHYYLAQLTS VRQWKTNDDT IDFDYTVLLH
241 ELSTQEIIPC RIHLVWYPGK PLKVKYHCQE LQTPEEASGT EEGSAVVPTE LSNFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RARRES1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.4
- Highest tissue expression
- 234 nTPM
Expression across tissuesHPA
Tissue
- adipose tissue: 234 nTPM
- fallopian tube: 173 nTPM
- salivary gland: 173 nTPM
- urinary bladder: 86 nTPM
- heart muscle: 85 nTPM
- prostate: 80 nTPM
Single-cell type
- endometrial secretory cells: 5,678 nCPM
- prostatic club cells: 3,434 nCPM
- conjunctival goblet cells: 3,280 nCPM
- submucosal glandular cells: 1,611 nCPM
- salivary ionocytes: 1,392 nCPM
- mesothelial cells: 1,281 nCPM
Immune cell
- naive B-cell: 0.1 nTPM
- non-classical monocyte: 0.1 nTPM
- plasmacytoid DC: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
Brain region
- choroid plexus: 28 nTPM
- cerebral cortex: 6.6 nTPM
- hippocampal formation: 6.4 nTPM
- cerebellum: 6.3 nTPM
- white matter: 5.9 nTPM
- basal ganglia: 5.4 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.61
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.82
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Latexin
- Cystatin superfamily
- Latexin-type cystatin domain
- Latexin
- Retinoic acid receptor responder protein 1
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of RARRES1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RARRES1 as an antibody target. Whether an autoantibody or antibody against RARRES1 could matter depends on whether native RARRES1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RARRES1 is annotated as secreted, so native RARRES1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label RARRES1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...